The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors
| Autor: | Samir Ali, Julian Symons, Isabel Najera, Sonal Rajyaguru, Hyunsoon Kang, Wen-Rong Jiang, Sophie Le Pogam, Nick Cammack, Matthew F. McCown |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_treatment
Hepatitis C virus Cytidine Hepacivirus Viral Nonstructural Proteins Biology Virus Replication medicine.disease_cause Antiviral Agents Deoxycytidine Drug Resistance Viral medicine Protease Inhibitors Pharmacology (medical) Protease inhibitor (pharmacology) Replicon Pharmacology NS3 Protease Nucleoside analogue Serine Endopeptidases Nucleosides Nucleoside inhibitor Virology Infectious Diseases Oligopeptides Nucleoside medicine.drug |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 52:1604-1612 |
| ISSN: | 1098-6596 0066-4804 |
| DOI: | 10.1128/aac.01317-07 |
| Popis: | Specific inhibitors of hepatitis C virus (HCV) replication that target the NS3/4A protease (e.g., VX-950) or the NS5B polymerase (e.g., R1479/R1626, PSI-6130/R7128, NM107/NM283, and HCV-796) have advanced into clinical development. Treatment of patients with VX-950 or HCV-796 rapidly selected for drug-resistant variants after a 14-day monotherapy treatment period. However, no viral resistance was identified after monotherapy with R1626 (prodrug of R1479) or NM283 (prodrug of NM107) after 14 days of monotherapy. Based upon the rapid selection of resistance to the protease and nonnucleoside inhibitors during clinical trials and the lack of selection of resistance to the nucleoside inhibitors, we used the replicon system to determine whether nucleoside inhibitors demonstrate a higher genetic barrier to resistance than protease and nonnucleoside inhibitors. Treatment of replicon cells with nucleoside inhibitors at 10 and 15 times the 50% effective concentration resulted in clearance of the replicon, while treatment with a nonnucleoside or protease inhibitor selected resistant colonies. In combination, the presence of a nucleoside inhibitor reduced the frequency of colonies resistant to the other classes of inhibitors. These results indicate that the HCV replicon presents a higher barrier to the selection of resistance to nucleoside inhibitors than to nonnucleoside or protease inhibitors. Furthermore, the combination of a nonnucleoside or protease inhibitor with a nucleoside polymerase inhibitor could have a clear clinical benefit through the delay of resistance emergence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|